Thu, Apr 17, 2014, 9:31 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • kennethtdc kennethtdc Jan 21, 2013 3:09 PM Flag

    How can you tell if an attorney is lying?

    His lips are moving..... I spoke to an underling at the law firm of Levi & Korsinsky. He explained that the options offered our CEO are in violation of our company,s bylaws. The suit would be against the Board members as individuals and not be against Insmed. I'm considering signing the retainer. I would like to hear "intellegent" reason for and against doing so.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Blasé, I somehow lost the reply button to your post so I am replying to you under my original post. I wanted to thank you for your civil and concise response to my uninformed post as to Mr. Lewis's compensation.

    • The answer to the question of who performed the DD and what were the findings on the safety file have never been answered. Supposedly LaBella and Glover did the DD and reported to Sharoky. Based upon this DD, Transave company was acquiered in December 2010. The bases reported were the Phase IIb CF/Pa results, an agreement with NIH to collaborate on an NTM clinical trial and marketing surveys suggesting multiple $300 million revenues. Four Phase III INDs were submitted and agreed upon with FDA in March 2011. Chiltren was hired to oversee CF/Pa studies (both US and Europe) after March 2011. Then Drucker was hired in late July 2011 and August 1, 2011 the FDA review of the preclinical safety data placed all INDs on "Hold." The FDA stopped the clinical trials because of two rats out of 100 in the carcinogenicity study with "lesions." Later Wedbrush leaked the fact that the finding in two rats was "foamy macrophages" which is a precancerous lesion in rat carcinogenicity studies, except these rats breathed liposomes daily for two years and would be expected to have "foamy macrophages." INSM management responded with a "??? scientific explanation" which resulted in the requirement for a carcinogenicity study in dogs for the NDA filing, a downgrade of the NTM study to Phase IIb, a delayed start of the Phase III CF/Pa trial in Europe to March 2012 and a $25.9 million impairment charge. Then there were costly "golden parachute" departures (Glover 2011, Tully, Labella and Whitten 2012) after all bonuses and stock options were awarded for their "underwhelming" performances. All this had to be approved by the BOD. The key question from the above timeline is "when did Transave management find out about any foamy macrophages and did they communicate that information to INSM?" Beyond that, why did the INSM DD not include direct conversations with the CROs that performed all the safety studies upon which the Phase III clinical trials were all based. Usually Phase III trials do not require any further preclinical animal studies of safety.

      But if the gripe is about Lewis coming in, cleaning house and getting things done, I fail to see a problem. He will have earned his remuneration and bonuses if a statistically significant number of patients from the CF/Pa study in Europe enter the extension study and do well and sometime soon the NTM study "beats the 84 day clock" for getting negative NTM cultures from 3 ml of sputum. Those would be significant clinical achievements that would demonstrate the value of Arikace. Also, I totally doubt the dog study will show any precancrous characteristics with any foamy macrophages found in the lungs. Highly doubtful.

      The only problem I see is mismanagement leading up to Lewis, but Sharoky and the BOD approved all the pre-Lewis mismanagement.

      Those are the issues I see.

      Sentiment: Buy

    • i would imagine that management is indemnified from any suit brought forth and you better believe that a suit would effect INSM, and not just management

    • Sharoky set out to see what he could afford.
      Transave lay dormant for a couple of years untill Insmed came in with money.

      The phase2 2009 results were looked at by those who invest in such companies?- No takers
      do you really believe any biotech that could be a blockbuster potential would not attract money or interest?

      Sharoky diluted old INSM shareholders by 35% and btw- that is exactly where we sit today 64 cents ! - 2 years+ after the deal.

      old shareholders paid off Transave debt ,were dealt a reverese split and paid for big compensation to old and new managment.

      Bringing in a hedge fund manager to manipulate the price so hedge funds - NOT Institutions- could make their cash up front and now carry no risk.

      what did Sharoky see? - A chance to make a lot of money without your vote without your say.

      I believe this is a credible information position in regards to the lawsuit

    • Could you please post the aforementioned bylaws that come into play? I would think that would help us, well at least me, come to an intelligent position.

      Thanks for your work in contacting L and K.

 
INSM
13.41+0.88(+7.02%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.